In fact, combining PD-L1 checkpoint blockade with YTHDF1 depletion enhances CD8+ T cell function and consequently slows tumor progression [123], providing a reference for the development of strategies utilizing m6A inhibitors in conjunction with PD-L1 therapy. The gene discussed is CD8A; the disease is neoplasm.